Marion Bertho (Caen, France)
Centre Francois BaclesseAuthor Of 1 Presentation
104P - HELENA : Study of HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer (ID 116)
- Marion Bertho (Caen, France)
- Francois Cherifi (Caen, France)
- Angelique Da Silva (Caen, France)
- Alison C. Johnson (Caen, France)
- Cecile Blanc Fournier (Caen, France)
- Antonin Broyelle (Lille, France)
- Olivia Abramovici (Lille, France)
- Adeline Morel (Caen, France)
- Ioana Hrab (Caen, France)
- Djelila Allouache (Caen, France)
- Carine Segura Djezzer (Caen, France)
- Christelle Levy (Caen, France)
- Clemence Boscher (Caen, France)
- Maud Villemin (Caen, France)
- Pauline Rottier (Caen, France)
- Justine Lequesne (Caen, France)
- George Emile (Caen, France)
Abstract
Background
HER2 expression has a prognostic and predictive impact in early breast cancer (BC). HER2-positive BC (score 3+ or 2+ with in situ hybridization (ISH) amplification) are treated with anti-HER2 therapies. HER2-low BC (score 1+ or 2+ without ISH amplification) are less defined and until now, no specific treatment has been provided for this subgroup. We tried to explore the response of HER2-low early BC to neoadjuvant chemotherapy (NAC) according to the HER2 score (1+ or 2+).
Methods
We designed a retrospective study in two French comprehensive cancer centers. All patient with HER2-low BC treated by NAC from January 2014 to December 2020 were included. First we analyzed the pathological complete response (pCR) to NAC with Sataloff or RCB score, according to the HER2 tumors score. Others objectives were to assess disease free survival (DFS) and overall survival (OS) according to HER2 score. Univariate and multivariate analysis were performed.
Results
We included 237 tumors of 229 patients. Of these, 160 (67.5%) tumors were HER2 1+ and 77 were HER2 2+. Hormone receptor (HR) were positive for 152 tumors (64.1%). The median age was 53.9 years. pCR was achieved in 38 tumors (17%) without difference between HER2 1+ and HER2 2+ subgroups (p=0.77). DFS and OS were statistically worse for HER2 1+ patients compared to HER2 2+ patients (Log-rank p=0.037 and p=0.042, respectively). After adjustment on age, HR and menopausal status, HER2 score was still associated with DFS and OS, with better survival for HER2 2+ patients (HR=0.35 [0.15-0.84], HR=0.24 [0.07-0.81] respectively).
Conclusions
In the HER2-low BC, no difference in pCR were observed between HER2 1+ and HER2 2+ but patients with HER2 2+ BC had a better DFS and OS than others. Further investigations are needed to confirm these results.
Legal entity responsible for the study
Centre François Baclesse.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Presenter Of 1 Presentation
104P - HELENA : Study of HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer (ID 116)
- Marion Bertho (Caen, France)
- Francois Cherifi (Caen, France)
- Angelique Da Silva (Caen, France)
- Alison C. Johnson (Caen, France)
- Cecile Blanc Fournier (Caen, France)
- Antonin Broyelle (Lille, France)
- Olivia Abramovici (Lille, France)
- Adeline Morel (Caen, France)
- Ioana Hrab (Caen, France)
- Djelila Allouache (Caen, France)
- Carine Segura Djezzer (Caen, France)
- Christelle Levy (Caen, France)
- Clemence Boscher (Caen, France)
- Maud Villemin (Caen, France)
- Pauline Rottier (Caen, France)
- Justine Lequesne (Caen, France)
- George Emile (Caen, France)
Abstract
Background
HER2 expression has a prognostic and predictive impact in early breast cancer (BC). HER2-positive BC (score 3+ or 2+ with in situ hybridization (ISH) amplification) are treated with anti-HER2 therapies. HER2-low BC (score 1+ or 2+ without ISH amplification) are less defined and until now, no specific treatment has been provided for this subgroup. We tried to explore the response of HER2-low early BC to neoadjuvant chemotherapy (NAC) according to the HER2 score (1+ or 2+).
Methods
We designed a retrospective study in two French comprehensive cancer centers. All patient with HER2-low BC treated by NAC from January 2014 to December 2020 were included. First we analyzed the pathological complete response (pCR) to NAC with Sataloff or RCB score, according to the HER2 tumors score. Others objectives were to assess disease free survival (DFS) and overall survival (OS) according to HER2 score. Univariate and multivariate analysis were performed.
Results
We included 237 tumors of 229 patients. Of these, 160 (67.5%) tumors were HER2 1+ and 77 were HER2 2+. Hormone receptor (HR) were positive for 152 tumors (64.1%). The median age was 53.9 years. pCR was achieved in 38 tumors (17%) without difference between HER2 1+ and HER2 2+ subgroups (p=0.77). DFS and OS were statistically worse for HER2 1+ patients compared to HER2 2+ patients (Log-rank p=0.037 and p=0.042, respectively). After adjustment on age, HR and menopausal status, HER2 score was still associated with DFS and OS, with better survival for HER2 2+ patients (HR=0.35 [0.15-0.84], HR=0.24 [0.07-0.81] respectively).
Conclusions
In the HER2-low BC, no difference in pCR were observed between HER2 1+ and HER2 2+ but patients with HER2 2+ BC had a better DFS and OS than others. Further investigations are needed to confirm these results.
Legal entity responsible for the study
Centre François Baclesse.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.